Pfizer reportedly started manufacturing hundreds of thousands of Covid-19 vaccines ahead of expecting approval in the US and elsewhere.
Keystone/Dave Weaver
The Swiss therapeutic products agency has begun reviewing another anti-Covid 19 vaccine in the rolling submission procedure.
This content was published on
1 minute
swissinfo.ch/ug
Português
pt
Swissmedic acelera processo de segunda vacina anti-viral
Swissmedic said the United States pharmaceutical company Pfizer submitted an application for the authorisation of a vaccine which is based on the mRNA technology last week.
The agency added it is fast-tracking all applications connected with the Covid-19 pandemic, assigning extra staff to this task so that content checks and, in particular, user safety are not compromised.
The criteria for reviewing safety, efficacy and quality remain unchanged, according to Claus Bolte, head of Swissmedic’s authorisation division.
“The data packages for the vaccine candidates will be reviewed just as comprehensively, but faster. As a result, we can shorten the waiting times between the development stages during the review,” Bolte said in a statementExternal link published on Monday.
Two weeks ago, the Swiss authorities started assessing an application for a vaccine developed by the British-Swedish company AstraZeneca and Oxford University.
Switzerland has also signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of its Covid-19 vaccine.
Popular Stories
More
Aging society
No house generation: the impossibility of buying property in Switzerland
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Swiss Abroad elect representatives online for first time
This content was published on
Swiss citizens in 50 countries have used electronic voting for the first time to elect representatives to the Council of the Swiss Abroad for the 2025-2029 legislative.
Nestlé scraps Nutri-Score food label in Switzerland
This content was published on
Nestlé plans to phase out its Nutri-Score nutrition labelling system on products sold in Switzerland. The food giant says it is almost the last company in the country to use it.
Swiss National Bank chairman warns of ‘great insecurity’ caused by US tariffs
This content was published on
The president of the Swiss National Bank (SNB), Martin Schlegel, has warned of the huge financial uncertainties caused by recent US tariffs.
Study: spring in Swiss Alps starts earlier and earlier
This content was published on
Climate change is transforming the Alps: after the snow cover disappears, plants in meadows and pastures are sprouting roughly six days earlier than 25 years ago.
This content was published on
The number of tourist coaches stopping at Schwanenplatz in the centre of Lucerne was down by two-thirds in April, compared to the same month last year.
Swiss-German border regions reaffirm stable Swiss-EU relations
This content was published on
Swiss and German officials have reaffirmed their commitment to stable and sustainable relations between Switzerland and the EU.
Pro-Palestinian protesters end University of Geneva demo
This content was published on
Pro-Palestinian protesters who camped out in front of the rector's office at the University of Geneva (UNIGE) left the premises on Thursday evening.
WEF courts Lagarde as next leader after founder’s abrupt exit
This content was published on
Klaus Schwab’s abrupt departure from the World Economic Forum has complicated carefully laid plans to persuade Christine Lagarde to assume the helm in a seamless transition.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid cure further away than hoped, says Novartis chief
This content was published on
Swiss pharmaceutical firm Novartis has rowed back on earlier predictions that a drug to combat coronavirus could be on the horizon.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.